CTOs on the Move

TechLab

www.techlab.com

 
TechLab is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.techlab.com
  • 2001 Kraft Dr
    Blacksburg, VA USA 24060
  • Phone: 540.953.1664

Executives

Name Title Contact Details

Similar Companies

Design Therapeutics

Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions.

InforMed Direct

InforMed Direct is a Haddam, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bora Pharmaceuticals

Bora Pharmaceuticals is a premier full-service, international CGMP CDMO specializing in complex oral solid dosage (tablet & capsules), liquids (solutions, suspensions, & nasal sprays) and semi-solids (creams & gels) pharmaceutical Rx and OTC products for late-phase Clinical through Commercial manufacturing and packaging.

Clene

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.